uniQure

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

uniQure reports solid Q1 results, advances AMT-130 gene therapy

uniQure's Q1 2025 performance showed steady revenue and strong financial position. Strengths include progress on AMT-130, enrollment updates, and breakthrough therapy designation. Challenges lie in regulatory processes, clinical study progress, and market competition. Opportunities exist in expanding AMT-130's reach, partnerships, and ongoing innovation in gene therapy.

uniQure reports solid Q2 earnings, advances key therapies successfully

uniQure's Q2 2025 earnings call showcased progress on key therapies, strong financial management, and promising early data for AMT-260. The company faces challenges in regulatory navigation and communication but holds opportunities for commercial success and continued innovation.

uniQure reports positive clinical data but faces FDA uncertainty

uniQure's Q3 performance reflected positive clinical outcomes for key gene therapies, alongside financial growth and a strong cash position. While facing regulatory uncertainties and safety concerns, the company remains committed to advancing its pipeline and exploring international markets. Challenges in FDA discussions and clinical trial pauses underscore the complexities of biopharmaceutical development, requiring strategic management of resources and priorities. Opportunities lie in expanding market reach, progressing clinical programs, and leveraging partnerships to drive future growth and establish uniQure as a leader in gene therapy innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.